Koch-HenriksenNThygesenLCStenagerE, et al. Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women. Neurology2018; 90(22): e1954–e1963.
2.
RibbonsKLeaRTiedemanC, et al. Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: A 50-year study. Mult Scler2017; 23(8): 1063–1071.
3.
HoutchensMKEdwardsNCPhillipsAL.Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS. Neurology2018; 91(17): e1570–e1578.
4.
NguyenALHavrdovaEKHorakovaD, et al. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Mult Scler Relat Disord2019; 28: 235–243.
5.
WebbEJDMeadsDEskyteI, et al. A systematic review of discrete-choice experiments and conjoint analysis studies in people with multiple sclerosis. Patient2018; 11(4): 391–402.
6.
AlroughaniR. Family planning is the second most relevant factor for treatment decisions after disease activity – Yes. Mult Scler2020; 26(6): 640–641.
7.
Oreja-GuevaraC. Family planning is the second most relevant factor for treatment decisions after disease activity – No. Mult Scler2020; 26(6): 642–643.
8.
NguyenALEastaughAvan der WaltA, et al. Pregnancy and multiple sclerosis: Clinical effects across the lifespan. Autoimmun Rev2019; 18(10): 102360.
9.
BoveRMcHenryAHellwigK, et al. Multiple sclerosis in men: Management considerations. J Neurol2016; 263(7): 1263–1273.
10.
GiovannoniGButzkuevenHDhib-JalbutS, et al. Brain health: Time matters in multiple sclerosis. Mult Scler Relat Disord2016; 9(Suppl. 1): S5–S48.
